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ImmunityThe function of the lectin pathway of complement activation in vivo against West Nile virus (WNV) or many
other pathogenic viruses has not been deﬁned. Mice deﬁcient in lectin pathway recognition molecules
(mannose binding lectin-A (MBL-A) andmannose binding lectin-C (MBL-C)) or the effector enzymemannan-
binding lectin-associated serine protease-2 (MASP-2), were more vulnerable toWNV infection than wild type
mice. Compared with studies of mice deﬁcient in factors of the classical or alternative pathway, MBL-A−/− ×
MBL-C−/− or MASP-2−/− mice showed a less severe course of WNV infection. Indeed, a deﬁciency in lectin
pathway activation did not signiﬁcantly affect the kinetics of viral spread to the central nervous system (CNS)
nor did it profoundly alter generation of adaptive B and T cell immune responses. We conclude that MBL-
mediated recognition and lectin pathway activation have important yet subordinate functions in protecting
against WNV infection and disease.e virus; CNS, central nervous
ssociated serine protease; PFU,
Molecular Microbiology, and
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+1 314 362 9230.
iamond).
l rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
Mannose-binding lectin (MBL) is a pattern recognition component
of the complement system that binds carbohydrate groups on the
surface of microbial pathogens and triggers the lectin activation
pathway of complement (Takahashi et al., 2006). In humans, one MBL
gene is expressed, whereasmice produce two closely related proteins,
MBL-A and MBL-C. MBL proteins are expressed primarily in the liver
and circulate in the blood, where they complex with mannan-binding
lectin-associated serine proteases (MASP) (Takahashi et al., 2007). In
addition to MBL, there is a family of structurally related plasma
proteins, called ﬁcolins, which may serve as carbohydrate recognition
molecules and drive lectin pathway mediated complement activation
upon binding to a pathogen surface. MBL and ﬁcolin engagement
activates the associated MASP-2, which cleaves the downstream
complement components C4 and C2 to form the C3 convertase
complex C4b2a. The cleavage of C3, results in C3a release and C3bdeposition (Ip et al., 2009). C3b marks pathogens for clearance by
phagocytosis through one of several complement receptors. Addi-
tionally, complement deposition targets pathogens for destruction by
forming a C5 convertase, C4b2a(C3b) that cleaves C5 to release the
complement anaphylatoxin C5a and the larger cleavage fragment C5b,
which promotes formation of the membrane-attack complex (MAC)
by the terminal (C5–C9) complement components.
MBL and ﬁcolins recognize many pathogens, including viruses,
bacteria and fungi, and are believed to function both in direct innate
immune restriction and induction of adaptive immunity. In humans,
inherited MBL deﬁciencies are common, and are caused by frequently
occurring polymorphisms in the MBL gene. MBL deﬁciencies are
associated with more severe disease after Neisseria meningitides
infection, and greater susceptibility to infection with HIV, hepatitis B
virus, hepatitis C virus, and herpes simplex virus (HSV) (Bathum et al.,
2006; Chonget al., 2005; Sasaki et al., 2000; Seppanen et al., 2009; Tan et
al., 2009). Studies inMBL-A−/−×MBL-C−/−micehave established a role
for MBL in limiting infections with Staphylococcus aureus, Pseudomonas
aeruginosa, Candida albicans, and herpes simplex virus (Gadjeva et al.,
2004; Held et al., 2008; Moller-Kristensen et al., 2006; Shi et al., 2004).
West Nile virus (WNV) is an enveloped, single-stranded positive
polarity RNA virus in the Flaviviridae family. The virus cycles between
mosquitoes and birds, but also infects humans, horses and other
vertebrate animals (Mackenzie et al., 2004). In humans, WNV
infection is often asymptomatic, or manifests with a mild fever;
Fig. 1.Mice deﬁcient in components of the lectin pathway aremore susceptible to lethal
WNV infection. Wild type (A, n=78; B, n=71),MBL-A−/− ×MBL-C−/− (n=65) (A), or
MASP-2−/− (n=70) (B) C57BL/6 mice were infected subcutaneously with 102 PFU of
WNV. Survival was monitored over the course of 22 days. Asterisks denote differences
that were statistically signiﬁcant (Pb0.05) as judged by the log rank test.
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individuals, it can cause life-threatening encephalitis (Diamond,
2009; Petersen et al., 2003). The immunological basis of protection
against WNV has been analyzed extensively in inbred mice, which are
susceptible to WNV encephalitis. From these studies, it is evident that
both innate and adaptive immune mechanisms are required for
protection against neuroinvasive disease. Mice deﬁcient in type I or II
interferon, or T cell subsets such as γδ, regulatory, CD4+ or CD8+ T
cells succumb to WNV disease with enhanced kinetics and frequency
(reviewed in Diamond et al., 2009; Samuel and Diamond, 2006).
Protection against WNV encephalitis also requires an intact
complement system as mice lacking the central complement compo-
nent C3 uniformly succumbed to infection (Mehlhop et al., 2005). Both
the classical and alternative activation pathways are required, as mice
deﬁcient in C1q (classical pathway) or fB (alternative pathway) also
showed greater susceptibility (Mehlhop and Diamond, 2006). As C4−/−
mice showedamore severephenotype afterWNV infection thanC1q−/−
mice, we hypothesized that the lectin pathway independently protects
against WNV infection. Consistent with this, mouse serum lacking MBL
showed a decreased ability to directly neutralize insect cell-derived
WNV in vitro (Fuchs et al., 2010).
Here, using mice that were genetically deﬁcient in MBL-mediated
pathway recognition and activation, we directly evaluated the contribu-
tion of MBL to immunity against WNV infection.MBL-A−/− ×MBL-C−/−
mice had relatively mild defects in WNV clearance, resulting in only
moderately enhanced susceptibility. Contrary to our expectations, the in
vivo studies revealed similar viral tissue burdens in several peripheral
organs between wild type and MBL-A−/− × MBL-C−/− mice. Further-
more, a deﬁciency inMBL genes did not signiﬁcantly impair induction of
adaptive antiviral immune responses. Thus, while the lectin pathway
contributes toprotectionagainstWNV, its effect is subordinate compared
to the antiviral and priming functions of the classical and alternative
pathways of complement activation.
Results
A deﬁciency of MBL or MASP-2 results in increased susceptibility to WNV
infection
We recently observed that MBL in serum can bind to insect cell-
derivedWNV, leading to complement activation and neutralization of
viral infectivity in vitro (Fuchs et al., 2010). To investigate whether
MBL contributes to immune protection in vivo, we infected MBL-
A−/− × MBL-C−/− mice on a C57BL/6 background with 102 PFU of
WNV via footpad injection (Fig. 1A). As seen previously (Samuel and
Diamond, 2006), ~30% of wild type C57BL/6 mice succumbed to WNV
infection. CongenicMBL-A−/− ×MBL-C−/−mice reproducibly showed
a small yet statistically signiﬁcant increased mortality rate (~55%,
Pb0.005). However, MBL-A−/− × MBL-C−/− mice showed similar
kinetics of survival with a mean time to death that was not
substantially different compared to wild type mice (mean time to
death of 11.6 versus 11.9 days, PN0.6). For both wild type and MBL-
A−/− × MBL-C−/− mice, animals that succumbed to WNV infection
showed similar clinical signs of encephalitis and limb paralysis. As our
previous studies suggested that MBL preferentially bound to insect
cell-derived WNV (Fuchs et al., 2010), we assessed whether infection
with mammalian cell-derived WNV altered the susceptibility inMBL-
A−/− ×MBL−C−/−mice. However, similar to insect-cell derived virus,
WNV propagated in Vero African green monkey cells also showed
greater virulence in MBL-A−/− × MBL-C−/− mice with increased
mortality observed (66% versus 24%, P=0.006) (data not shown).
MBL proteins associatewithMASPmolecules to trigger downstream
complement activation, with MASP-2 believed to be the functionally
dominant serine protease (Gal et al., 2009). Infection of congenicMASP-
2−/− mice with WNV showed a similar phenotype of modestly
increased susceptibility to lethal infection (Fig. 1B, Pb0.0005). Overall,an absence of key components of the lectin activation pathway resulted
in increased susceptibility to WNV infection, although the difference
was less than that observed with deﬁciencies in either the classical or
alternative pathways (Mehlhop and Diamond, 2006).
Viral burden in wild type and MBL-A−/− × MBL-C−/− mice after
subcutaneous infection
To begin to determine the cause for the higher mortality, we
measured viral burden in tissues from WNV-infected wild type and
MBL-A−/− × MBL-C−/− mice at several time points after infection.
Because of its ability to neutralize insect cell-derived WNV (Fuchs
et al., 2010), we hypothesized that MBL would limit viral spread at
early time points in lymphoid tissues or the intravascular compart-
ment. Surprisingly, no statistical difference in magnitude or kinetics of
WNV infection was observed in the draining inguinal lymph node,
serum, or spleen of wild type mice and MBL-A−/− × MBL-C−/− mice
(Figs. 2A, B, and C, PN0.1). At day one after infection, we found slightly
lower levels of WNV RNA that did not achieve statistical signiﬁcance
in the draining lymph node of MBL-A−/− × MBL-C−/− mice, as half of
the samples had undetectable levels of viral RNA. However, by day 2,
no difference in WNV RNA was observed, conﬁrming that viral
Fig. 2. WNV tissue burden and spread in mice after subcutaneous infection.MBL-A−/− ×MBL-C−/− and wild type mice were infected subcutaneously with WNV. At the indicated time
points, tissueswere harvested and analyzed for viral titers by quantitative RT-PCR ((A–B) inguinal lymph node and serum) or plaque assay ((C–F) spleen, kidney, brain, spinal cord). Data
from10 to 24mice per time point are shown asWNV genome equivalents per μg 18S RNA (A, B) or as PFU per gramof tissue (C–F). Dotted lines indicate the limit of detection of the assay.
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affected by the absence of MBL-A and MBL-C.
In several immunodeﬁcient mice lacking key proteins that
function in innate and adaptive immunity, WNV replicates to high
levels in visceral tissues such as the kidney or liver (Dafﬁs et al., 2008;
Diamond et al., 2003; Samuel and Diamond, 2005). However, MBL-
A−/− × MBL-C−/− mice showed little capacity to sustain WNV
infection in these tissues (Fig. 2D). Consistent with these ﬁndings,
dissemination to the brain and spinal cord occurred with the same
kinetics in wild type and MBL-A−/− × MBL-C−/− mice. Beginning at
days 6 and 8, WNV was detected in the brain and spinal cord of wild
type and MBL-A−/− × MBL-C−/− mice (Figs. 2E and F). While we
observed an overall trend towards increased WNV replication in the
CNS of MBL-A−/− × MBL-C−/− mice, this did not reach statistical
signiﬁcance despite the inclusion of large numbers of mice (PN0.2,
n=15 (day 8); n=24 (day 10)).
As seen previously in adult C57BL/6 mice (Brown et al., 2007;
Diamondet al., 2003), the viral burdendata in the brain and spinal cord
did not ﬁt a Gaussian distribution; while most mice sustained high
titers, a subset was below the limit of detection (~102 to 103PFU/g) of
the plaque assay. The latter data points may reﬂect a relatively low or
complete absence of CNS infection in this 8 to 12 week-old age cohort.
As the few “negative” data points could create sufﬁcient variability to
limit detection of differences in the cohort of mice that showed
deﬁnitive CNS infection, we stratiﬁed the viral burden data and
compared samples with documented spread to the brain and spinal
cord. Using this analysis, differences in viral burden at day 10 between
wild type and MBL-A−/− × MBL-C−/− mice while still small, became
more pronounced in the brain (1.3×104 versus 4.3×104PFU/g,
P=0.07) and spinal cord (4.5×104 versus 1.4×105PFU/g, P=0.05).
Overall, an absence of MBL resulted in a small increase in WNV
lethality thatwas associatedwith relativelymodest differences in viral
replication at late times after infection in the CNS.
WNV replication in wild type and MBL-A−/− × MBL-C−/− mice after
intracranial infection
Themodest increase in viral infection in theCNSofMBL-A−/−×MBL-
C−/− mice at only late time points suggested a possible direct innate
immune effect of MBL that restricted replication in neuronal tissues.
Prior studies have established thatMBL andMASP are deposited in braintissue during inﬂammatory or ischemic insults (Pedersen et al., 2009).
To assess whether the lectin pathway could have a more direct effect in
the CNS, we infected wild type and MBL-A−/− × MBL-C−/− mice with
WNV by an intracranial route and measured viral titers in different
regions of the CNS at days 2, 4 and 6 after infection. WNV replicated
rapidly in neuronal tissues, reaching high (1 to 5×107PFU/g) titers at
days 4 and 6 after infection in multiple regions including the cortex,
brainstem, cerebellum, and spinal cord. However, no difference in the
kinetics of spread or magnitude of replication was observed in CNS
tissues from MBL-A−/− × MBL-C−/− mice (Fig. 3, PN0.6). These results
suggest that the increased viral burden in CNS tissues at late times after
subcutaneous infection was not due to a direct effect of MBL.
The effect of an MBL deﬁciency on T and B cell responses to WNV
Given the intracranial challenge results, we hypothesized that the
differences in viral burden and mortality after subcutaneous WNV
infection could be due to altered adaptive immunity. Complement
activation is known to augment adaptive immune responses by
facilitating antigen uptake and presentation and lowering the
threshold for B cell activation (Carroll, 2004). Moreover, prior studies
have shown defects in adaptive B and T cell responses in mice lacking
components of the classical and alternative pathways of complement
activation (Mehlhop and Diamond, 2006). However, detailed studies
on the development of antigen-speciﬁc immune responses against
pathogens in MBL-A−/− × MBL-C−/− mice have not been performed.
To investigate the contribution of MBL to adaptive immune responses,
we examined WNV-speciﬁc T cell and antibody responses.
To evaluate WNV-speciﬁc T cell responses, wild type and MBL-
A−/− × MBL-C−/− mice were infected subcutaneously with WNV. At
day 7, the percentage and number of IFN-γ-secreting splenic CD4+
and CD8+ T cells after ex vivo restimulation with immunodominant
WNV peptides or PMA and ionomycin were measured by ﬂow
cytometry (Figs. 4A, B, and C). Notably, spleens from wild type and
MBL-A−/− × MBL-C−/− mice contained similar percentages and
numbers of stimulated and WNV-speciﬁc CD4+ and CD8+ T cells
(Figs. 4A, B and data not shown). To conﬁrm that the WNV-speciﬁc
CD8+ T cells were equivalently cytolytic in MBL-A−/− × MBL-C−/−
mice, an in vivo killing assay was performed. At 8 days after WNV
infection, CD45.2+ wild type or MBL-A−/− × MBL-C−/− mice were
injectedwith amixture of CFSE-labeledWNV peptide-pulsed CD45.1+
Fig. 3. WNV tissue burden and spread in the CNS after direct intracranial inoculation. MBL-A−/− × MBL-C−/− and wild type mice (n=4 to 6 mice per time point) were infected
intracranially with 101 PFU of WNV, and CNS regions (A, cerebral cortex; B, brain stem; C, white matter; and D, cerebellum) and (E) spinal cord were harvested at indicated time
points. Viral titers were determined by plaque assay. Data are shown as PFU per gram of tissue. Dotted lines indicate the limit of detection of the assay.
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target cells. Six hours later, spleens were harvested and the percentage
of remaining WNV peptide-pulsed target cells was determined.
Compared to wild type mice, MBL-A−/− × MBL-C−/− mice showed
slightly lower (69 versus 83%) levels of antigen-speciﬁc cytotoxicity but
this difference did not attain statistical signiﬁcance (Figs. 4D and E,
PN0.2). Overall, our analysis of WNV-speciﬁc T cell responses did not
provide compelling evidence for an essential role of MBL in generating
peripheral CD4+ and CD8+ responses against WNV.
Although peripheral T cell responses against WNV appeared
normal in MBL-A−/− × MBL-C−/− mice, we assessed whether
leukocyte migration to the inﬂamed brains might be impaired, as
this also can result in enhanced viral replication in CNS tissues (Glass
et al., 2005; Klein et al., 2005). We infected wild type andMBL-A−/− ×
MBL-C−/− mice subcutaneously with WNV and analyzed CD45+
leukocyte subsets within brains at day 8 by ﬂow cytometric analysis.
Notably, we observed no difference in accumulation of WNV-speciﬁc
CD8+ T cells between wild type and MBL-A−/− × MBL-C−/− mice as
judged after restimulation of brain leukocytes with a Db-restricted
WNV immunodominant NS4B peptide (Figs. 5A and B). Analogously,
no signiﬁcant difference in the leukocyte subset composition was
detected between wild type and MBL-A−/− × MBL-C−/− mice, as the
total number of CD45+ leukocytes, CD4+ T cells, CD8+ T cells, CD19+
B cells, activated macrophages and microglia was equivalent (Fig. 5C
and data not shown). Thus, an absence of MBL-A and MBL-C did not
alter the trafﬁcking or accumulation of antigen-speciﬁc or other
inﬂammatory leukocytes in the brain after WNV infection.
We next measured WNV-speciﬁc antibody responses in wild type
and MBL-A−/− × MBL-C−/− mice. Levels of WNV E protein-speciﬁc
IgM and IgG in sera from infected mice were equivalent at days 6,
8 and 10 (Figs. 6A and B, PN0.5). Effective anti-WNV antibody
responses in C57BL/6 mice are characterized by a dominance of
complement-ﬁxing IgG2b and IgG2c antibody isotypes, whereas
WNV-speciﬁc IgG1 is typically observed at lower levels (Mehlhop
and Diamond, 2006). This pattern was sustained inMBL-A−/− ×MBL-
C−/− mice, where antigen-speciﬁc IgG2b levels were equivalent to
those in wild type sera (Fig. 6C, PN0.9). To compare the functional
activity of WNV-speciﬁc antibodies, we performed a focus reductionneutralization assay in which virions were pre-incubated with serial
dilutions of heat-inactivated serum from infected animals. We
observed a small (1.4-fold) reduction in neutralizing activity of sera
fromMBL-A−/− ×MBL-C−/−mice at day 8 after infection that attained
statistical signiﬁcance (Fig. 6D, Pb0.05). Neutralizing antibody titers,
however, were not signiﬁcantly different at day 10 after infection.
Overall, a deﬁciency of MBL had modest effects on antigen-speciﬁc
antibody production, with only a transient impact on neutralizing
antibody titers.
Discussion
This report extends our understanding of how different comple-
ment activation pathways confer protection against WNV, a patho-
genic enveloped RNA virus. We demonstrate that mice deﬁcient in the
lectin pathway recognition and activation (MBL-A−/− × MBL-C−/− or
MASP-2−/−) show a small but statistically signiﬁcant increased
mortality rate after WNV infection. This ﬁnding indicates that MBL
recognition of WNV contributes to protection against WNV infection.
Somewhat unexpectedly, a deﬁciency of lectin pathway activation did
not alter the kinetics or the magnitude of viral spread to different
organs, nor did it profoundly affect development of adaptive immune
responses.
Prior studies demonstrated that mice lacking the central comple-
ment component C3 were completely vulnerable to peripheral
inoculation with the same low dose (102 PFU) of virulent WNV
(Mehlhop et al., 2005). In comparison, C1q−/− mice, which fail to
activate the classical pathway efﬁciently, or factor B−/− mice, which
are defective in alternative pathway activation, showed higher but
incomplete (83% and 96%, respectively) mortality rates at the same
viral dose compared to the ~30% observed in congenic wild type mice
(Mehlhop and Diamond, 2006). A role for the C4-dependent and C1q-
independent lectin pathway of complement activation in restricting
WNV infection was inferred because the phenotype of C4−/− mice
was more severe than that observed with C1q−/− mice. Our results
conﬁrm that the lectin pathway is essential for efﬁcient control of
WNV infection. However, the rather subtle nature of the phenotype, at
both the virological and immunological levels, suggests that lectin
Fig. 4.WNV-speciﬁc T cell responses remain intact in MBL-A−/− × MBL-C−/− mice. A–C. Wild type and MBL-A−/− × MBL-C−/− mice were infected subcutaneously with 102 PFU of
WNV. Seven days later, spleens were harvested and splenocytes were (A) restimulated in vitro with Db-restricted WNV NS4b peptide or I-Ab-restricted WNV NS3 peptides or (B)
activated with PMA and ionomycin. Six hours later, CD8+ and CD4+ T cells were analyzed for the expression of intracellular IFN-γ by ﬂow cytometry. Data are combined from three
independent experiments with a total n=9 mice per group. C. A representative ﬂow cytometry dot plot showing intracellular IFN-γ staining following Db-restricted WNV NS4B
peptide re-stimulation comparing samples from wild type or MBL-A−/− × MBL-C−/− mice. Numbers in dot plots indicate the percentage of IFN-γ+ cells within the CD8+ T cell
population. D–E. CD8+ T cell cytotoxicity function remains intact inMBL-A−/− ×MBL-C−/−mice. Eight days after subcutaneous WNV infection, wild type orMBL-A−/− ×MBL-C−/−
CD45.2+ mice were given CD45.1+ target cells (CFSE+WNV NS4b-pulsed naive splenocytes or CSFE− control unpulsed splenocytes) by intravenous administration. Six hours later,
mice were sacriﬁced and splenocytes were analyzed for the ratio of peptide pulsed to non-pulsed cells by interrogating cells in the CD45.1 gate. D. The percentage of in vivo killing
was calculated by determining the ratio of peptide-pulsed versus unpulsed cells for each mouse, and by normalizing to that seen in naive mice. Data is combined from two
independent experiments with a total of four WNV-infected mice per group. E. Representative ﬂow cytometry plots showing differential killing of target cells in naive and WNV-
infected mice.
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pathway activation against WNV.
At ﬁrst glance, these results appear to contrast with our recent study
in which MBL bound to high- or pauci-mannose-containing carbohy-
drates on insect cell-derived WNV and neutralized viral infectivity in
vitro (Fuchs et al., 2010). Based on cell culture experiments, we
predicted that MBL served as an extracellular pattern recognition
element that neutralizedWNVdirectly. Surprisingly,we didnot observe
early or more rapid dissemination of WNV or a defect in adaptive
immune priming inMBL-A−/−×MBL-C−/−mice.WNV infection spread
with similar kinetics in blood and tissues, and the disease coursewasnot
accelerated compared towild typemice. Rather, the increasedmortality
rate in MBL-A−/− × MBL-C−/− mice was associated with small
differences in viral tissue burdens at late time points after infection in
the CNS. However, in the original study, MBL had potent neutralizing
functions only on WNV derived from insect cells, and not on virus
generated inmammalian cells (Fuchs et al., 2010), because the N-linked
glycans on the virion failed to bind MBL efﬁciently after processing to
complex and hybrid carbohydrates. Thus, after subcutaneous infection,
once WNV undergoes one round of replication in mouse cells, it
becomes resistant to MBL-mediated neutralization. In comparison,mammalian cell-generated dengue virus (DENV), a related ﬂavivirus,
remains susceptible to MBL-mediated neutralization (Fuchs et al., 2010).
This is due to the display of a secondN-linked glycanon the viral envelope
protein that retains a high mannose glycan even when produced in
mammalian cells (Hacker et al., 2009). We predict that MBL may have
greater protective functions against viruses such as DENV, which display
ligands for MBL after animal infection. Unfortunately, since inbred mice
inherently are highly resistant to DENV infection with the exception of
those lacking both type I and II IFN signaling (Johnson and Roehrig, 1999;
Shresta et al., 2004), currently, it is not possible to study the function of
MBL in vivo against DENV using the available deﬁcient mice.
Complement deﬁciencies can impact adaptive immune responses,
as seen in CR2−/− or C3−/− mice in which antibody and/or T cell
responses are attenuated, respectively (Ahearn et al., 1996; Carroll,
2004; Kopf et al., 2002; Marsh et al., 2001). A speciﬁc role for MBL in
modulating antigen-speciﬁc IgM and IgG responses has been
described (Carter et al., 2007; Guttormsen et al., 2009; Lawrence
et al., 2009; Muller et al., 2010). However, some of the observed
differences in antibody production may be due to use of a mixed
genetic background form of the MBL-A−/− × MBL-C−/−. Indeed, no
difference in antibody response was observed by another group that
Fig. 5. MBL-A−/− × MBL-C−/− mice show similar accumulation of leukocytes in the brain following WNV infection. Wild type and MBL-A−/− × MBL-C−/− mice were infected
subcutaneously with WNV. At day 8 after infection, brains were harvested and the leukocyte compartment within the brain tissue was analyzed by ﬂow cytometry for the (C)
percentage and numbers of total leukocytes, T cell subsets, CD11b+ CD45−microglia and CD11b+ CD45+ activated macrophages A–B. Leukocytes were restimulated in vitro with a
Db-restricted NS4B peptide, and percentages and total numbers ofWNV-speciﬁc IFN-γ-secreting CD8+ T cells (after NS4B peptide stimulation) or total activated IFN-γ+ CD8+ T cells
(after anti-CD3 stimulation) were determined. Data was pooled from experiments with 5 to 8 individual mice.
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et al., 2009). Our experiments revealed only small differences in the
quality of neutralization or quantity of antibody response or antigen-
speciﬁc function of CD4+ or CD8+ T cells in the context of WNV
infection in fully-backcrossed MBL-A−/− × MBL-C−/− mice.
In addition to MBL, the lectin pathway can be activated
independently by ﬁcolins, which recognize alternative carbohydrateFig. 6. MBL-A−/− × MBL-C−/− mice generate efﬁcient WNV-speciﬁc antibody responses
subcutaneously with WNV. At the indicated time points, serum was harvested, serially dilut
endpoint titer analysis. C. At day 10, WNV-speciﬁc IgG1 and IgG2b were measured using isot
D. Sera from the indicated days after infection were also tested for neutralizing activity usin
focus formation by 50%. Asterisks denote differences that were statistically signiﬁcant (Pb0.0
lines indicate the limit of detection of the assay.ligands, such as acetylated or sulfated oligosaccharides (Garlatti et al.,
2009; Gout et al., 2010; Krarup et al., 2008). It is conceivable that
ﬁcolins could substitute and thus explain the relatively modest viral
and immunological phenotypes in MBL-A−/− × MBL-C−/− mice. Two
experiments suggest against this: (a) MBL-A−/− × MBL-C−/− mouse
serum (which contains ﬁcolins) was unable to deposit complement or
neutralize WNV in vitro (Fuchs et al., 2010); and (b) although ﬁcolin-during primary infection. Wild type and MBL-A−/− × MBL-C−/− mice were infected
ed, and WNV E protein-speciﬁc IgM (A) and IgG (B) were measured by ELISA using an
ype-speciﬁc secondary antibody reagents. Data are shown as reciprocal endpoint titers.
g a focus reduction assay. Indicated data points represent serum dilutions that reduced
5) as judged by the Mann–Whitney test. Data are from 10 to 23 mice per group. Dotted
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still requires MASP-2, the major serine protease that activates C4 and
C2 after MBL or ﬁcolin binding (Gal et al., 2009). The rather subtle
phenotype ofMBL-A−/− ×MBL-C−/−mice in vivo after WNV infection
independently was conﬁrmed inMASP-2−/−mice, which also showed
modestly increased mortality yet small differences in tissue viral
burden (data not shown). Nonetheless, a deﬁnitive conﬁrmation of
the role of the lectin pathway in immunity to WNV may await
infection studies with mice with multiple deﬁciencies (MBL-A−/− ×
MBL-C−/− × ﬁcolin−/− or MASPnull (MASP-1/3−/− × MASP-2−/−)),
which have not been generated or remain unavailable.
MBL has previously been suggested to contribute to protective
immunity against several pathogens, including bacteria, viruses, fungi,
and parasites. Analogous to our studies, direct MBL binding and
modest neutralization of HSV-2 virions were demonstrated (Gadjeva
et al., 2004). Infection of MBL-A−/− × MBL-C−/− mice with HSV-2
resulted in higher viral loads in liver, but not in spleen or brain. In
other studies, decreased survival ofMBL-A−/− ×MBL-C−/−mice after
S. aureus or C. albicans infection was attributed to altered cytokine
responses, reduced phagocytosis, or delayed leukocyte inﬁltration
into affected tissues (Held et al., 2008; Shi et al., 2004). MBL has been
reported to interact with Toll-like receptors 2 and 6 to promote
cytokine secretion in response to pathogen recognition (Ip et al.,
2008). Thus, it remains possible that the modestly enhanced
susceptibility of MBL-A−/− × MBL-C−/− mice during WNV infection
is modulated in part, by altered cytokine responses, although this did
not appear to affect viral titers in blood or peripheral tissue
compartments.
This study expands our knowledge of the in vivo mechanisms of
complement-mediated antiviral immunity. While MBL and the lectin
activation pathway contribute to control of WNV infection in vivo, the
phenotype was subtle compared to that observed with deﬁciencies in
components of the classical or alternative activation pathways. For
WNV, an arthropod-borne ﬂavivirus, the modiﬁcation of N-linked
glycans on the virion structural proteins to complex carbohydrates,
which occurs within one round of replication in animal cells, likely
overcomes much of the direct inhibitory effect of MBL. Although we
observed slightly higher WNV levels in the brain in MBL mice, which
correlatewith an enhancedmortality rate, the rathermodest phenotype
precluded further delineation of the speciﬁc mechanism. Based on
extensive immunological analysis, a deﬁciency in MBL did not cause
major defects in adaptive Bor T cell responses. Although the studieswith
WNV suggest a relatively small effect, it remains intriguing to consider
that severe infection of other ﬂaviviruses (e.g., DENV) in humans could
be associatedwithMBL deﬁciencies or polymorphisms that result in low
expression or functionally impaired MBL (Thiel et al., 2006).
Materials and methods
Mice
MBL-A−/− × MBL-C−/− mice on a C57BL/6 background and
congenic wild type mice were purchased from Jackson Laboratories.
MASP-2−/− mice on a C57BL/6 background were obtained commer-
cially (Omeros, Inc). All mice were housed in a pathogen-free mouse
facility at Washington University School of Medicine. Studies were
performed in compliance and with approval of the Washington
University School of Medicine Animal Safety Committee. B6.SJL
(CD45.1) mice were purchased from Taconic.
Cell lines and virus stocks
BHK21-15, Vero, and C6/36 Aedes albopictus cells were propagated
as previously described (Diamond et al., 2003). The New York strain of
WNV (WNV-NY)was generated from an infectious cDNA clone (strain
385–99) as described previously (Beasley et al., 2005), and passagedonce in C6/36 A. albopictus insect cells. BHK21–15 cells were used to
measure viral titer of infected cells or tissues by plaque assay
(Diamond et al., 2003).
Infection of mice
For in vivo studies, age- and gender-matched 8 to 12 week old
mice were infected with 102 PFU of WNV diluted in Hank's balanced
salt solution (HBSS) supplemented with 1% heat-inactivated fetal
bovine serum (FBS). Virus was administered subcutaneously (by
footpad injection in a volume of 50 μl). Intracranial inoculation was
performed by injecting 101 PFU of WNV in 10 μl HBSS/1% heat-
inactivated FBS. Virus preparations were tested for endotoxin
(Associates of Cape Cod) and found to be less than 0.25 EU/ml.
Quantiﬁcation of viral tissue burden and viremia
To monitor viral spread in vivo, mice were infected as described
above, and sacriﬁced at speciﬁc time points after inoculation. After
extensive cardiac perfusion with PBS, organs were harvested,
weighed, homogenized, and virus titers were determined by standard
plaque assay on BHK21 cells as described (Diamond et al., 2003). Viral
burden in serum and lymph nodes was determined by quantitative
RT-PCR using WNV-speciﬁc primers and probe as described (Samuel
et al., 2006). Lymph node RNA was normalized by measuring 18S
rRNA content in parallel using the 18S Taqman kit from Applied
Biosystems.
Antigen-speciﬁc T cell responses
WNV-speciﬁc CD4+ and CD8+ T cell responses were measured
after restimulation of splenic T cells ex vivo with WNV speciﬁc
peptides followed by intracellular cytokine staining for IFN-γ as
described previously (Brien et al., 2007, 2008; Purtha et al., 2007).
Brieﬂy, seven days after infection mice were euthanized and
splenocyte suspensions (2×107 cells/well) were prepared and
cultured in 96 well plates in the presence of Golgi Plug (BD
Biosciences) and 1 μM of the Db-restricted NS4b peptide (Purtha
et al., 2007) or the IAb-restricted NS3 peptides (Brien et al., 2008). Six
hours later, cells were washed and stainedwith ﬂuorochrome-labeled
antibodies to CD4 and CD8 (BD Biosciences). Cells were ﬁxed in 2%
paraformaldehyde, permeabilized in saponin buffer (0.5% saponin,
0.1% BSA in PBS), and incubated with Alexa 647-conjugated anti-IFN-
γ antibody (eBioscience). Cells were then washed and analyzed on a
FACSCalibur cytometer (BD Biosciences). The frequency and number
of WNV-speciﬁc T cells were determined based on the percentage of
IFN-γ+ cells within the CD4+ and the CD8+ T cell gate following
peptide stimulation. Staining on unstimulated or PMA (125 ng/ml)
and ionomycin (5 μg/ml)-treated splenocytes was performed as
negative and positive controls, respectively.
CD8+ T cell cytotoxicity was evaluated using an in vivo target cell
killing assay. As targets, splenocytes from B6.SJL (CD45.1) mice were
harvested and divided into two tubes. Half of the cells were labeled
with 1 μM CFSE according to standard protocols (Molecular Probes).
Labeled cells were incubated for 1 h at 37 °C with 1 μM of the Db-
restricted NS4b peptide. Cells were washed, counted and mixed (1:1
ratio) with unlabeled cells that were not exposed to peptide. The cell
mixture (107 total cells) was injected intravenously into naive or
WNV-infected (day 8 after inoculation) CD45.2 WT or MBL-A−/− ×
MBL-C−/− mice. After 6 h, mice were sacriﬁced and splenocytes were
incubated with conjugated antibodies to CD45.1 and CD45.2. Target
cells were identiﬁed by gating on CD45.1+ splenocytes. The
percentage of killing was calculated by determining the ratio of
CFSE+ cells versus CFSE− cells for each WNV-infected mouse, and by
normalizing for the ratio seen in naive mice: (1−(ratio WNV
infected/ratio naive))×100.
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Brain inﬁltrating CD4+ and CD8+ T cells, macrophages and
microglia were isolated and quantiﬁed as previously described
(Szretter et al., 2009). Intracellular IFN-γ staining of brain lympho-
cytes was performed as described above. CD3 stimulation was
performed with hamster anti-mouse CD3 (clone 145-2C11, BD
Bioscience) for 6 h in the presence of Golgi Plug prior to intracellular
staining for IFN-γ. Lymphocytes were processed on an LSRII (BD
Biosciences) using FACS Diva 6.1.1 (BD Biosciences) and analyzed
with FlowJo software (Treestar). Additional antibodies for six-color
analysis included: PerCP-Cy5.5 anti-CD8β (Biolegend), Paciﬁc blue
anti-CD4 (Invitrogen), Alexa 647 anti-IFN-γ (Biolegend), Alexa-700
anti-CD45 (Biolegend), and PE anti-CD11b (BD Bioscience). The total
number of speciﬁc cells was determined by multiplying the
percentage of positive cells by the total number of brain lymphocytes
harvested.
WNV-speciﬁc antibody responses
WNV-speciﬁc antibody titers weremeasured by ELISA as described
previously (Oliphant et al., 2007). Brieﬂy, individual wells of a
microtiter plate were coated overnight at 4 °C with 5 μg/ml of
recombinant WNV E protein. Plates were washed and blocked with
1% bovine serum albumin in PBS/0.05% Tween 20 (blocking buffer).
Serum samples from naive or WNV-infected mice were heat
inactivated (56 °C for 30 min), serially diluted in blocking buffer,
and added to wells for 1 h at 37 °C. Following several washes, biotin-
conjugated goat anti-mouse IgG or IgM (Sigma Aldrich), IgG1 or IgG2b
(BD Biosciences) (1 μg/ml in blocking buffer) was added for 1 h at
room temperature. Plates were then washed and incubated with
streptavidin-conjugated horseradish peroxidase (2 μg/ml in blocking
buffer; Vector Labs) for 1 h at room temperature. After several
washes, plates were developed with tetramethylbenzidine substrate
(Pierce) and the reaction was stopped with 1 N H2SO4. The OD450
was measured and adjusted by subtracting the OD450 of BSA-control
wells. Best-ﬁt curves were calculated using Prism (GraphPad
Software) for each serum dilution series and endpoint titers were
determined as three standard deviation units above background
signal.
The neutralizing activity of serum antibodies against WNV was
assessed using a focus reduction neutralization assay that was
modiﬁed from a published protocol for dengue virus (Brien et al.,
2010). WNV (2.4×102 PFU in DMEMwith 5% FBS) was pre-incubated
with serial dilutions (in DMEM with 5% FBS) of heat-inactivated
mouse serum at 37 °C for 30 min. Virus-serum mixtures were added
in duplicate to individual wells of tissue culture 96-well microtiter
plates containing Vero cells at ~90% conﬂuency. Virus was incubated
with Vero cells for 1 h at 37 °C, after which wells were overlaid with
1% carboxymethylcellulose (Sigma) inMEMwith 4% FBS. After culture
at 37 °C for 24 h, overlaymedia were removed andwells werewashed
with PBS. Cells were ﬁxed with 1% paraformaldehyde in PBS (10 min
at room temperature) and permeabilized with 0.1% saponin and 0.1%
BSA in PBS (saponin buffer; 5 min at room temperature). Cells were
stained with humanized E16 (Oliphant et al., 2005) (50 μl at 200 ng/
ml in saponin buffer) for 2 h at room temperature. Following several
washes, wells were incubated with horseradish peroxidase-conjugat-
ed anti-human IgG antibody (Sigma; 250 ng/ml in saponin buffer) for
1 h at room temperature. Wells were washed and infectious foci were
visualized with TrueBlue Substrate (KPL) after a 5 to 10 minute
incubation at room temperature. Wells were rinsed with water and
dried prior to analysis with a Biospot counter (Cellular Technology)
using Immunocapture software. Neutralization curves (% reduction in
spot numbers in samples pre-incubated with serum compared to
wells with virus pre-incubation with medium alone) were graphed
using Prism software, and EC50 values were calculated.Statistical analysis
In vitro experiments were analyzed with a two-tailed T-test. To
analyze viral tissue burdens, differences in log titers were analyzed by
the Mann–Whitney test. Kaplan–Meier survival data was analyzed by
the log rank test. All statistical analyses were performed with Prism
software.
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